SCHEMBL5751035

SCHEMBL5751035

CSc1ccc2cc(Br)ccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.52
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
SLC6A4 P31645 2/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
AKR1C3 P42330 3/20 0.43
AKR1C2 P52895 3/20 0.43
NCEH1 Q6PIU2 1/20 0.43
HRH3 Q9Y5N1 2/20 0.42
AHR P35869 2/20 0.40
NR4A2 P43354 1/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
BACE1 P56817 2/20 0.38
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556399 0.93 CYP2A6 (0.50) CYP2A6ALDH1A1KDM4EMEN1MAPT
SCHEMBL3954151 0.85 TYMS (0.40) CYP2A6ALDH1A1KDM4EMEN1MAPT
SCHEMBL29740644 0.84 AKR1C3 (0.52) CYP2A6ALDH1A1KDM4EMAPTSLC6A4
SCHEMBL8637909 0.84 AKR1C3 (0.52) CYP2A6ALDH1A1KDM4EMAPTSLC6A4
SCHEMBL4074405 0.80 CYP2A6 (0.56) CYP2A6ALDH1A1KDM4EMEN1MAPT
SCHEMBL29180421 0.79 AKR1C3 (0.48) CYP2A6ALDH1A1KDM4EMAPTSLC6A4
SCHEMBL192166 0.79 CYP2A6 (0.77) CYP2A6ALDH1A1KDM4EMEN1MAPT
SCHEMBL29353067 0.79 CYP2A6 (0.77) CYP2A6ALDH1A1KDM4EMEN1MAPT
SCHEMBL21551821 0.76 AKR1C3 (0.45) CYP2A6ALDH1A1KDM4EMAPTSLC6A4
SCHEMBL29740639 0.76 AKR1C3 (0.45) CYP2A6ALDH1A1KDM4EMAPTSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084149-B2 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-08-01 US disclosed
EP-1073640-B1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL (JP) 2005-04-13 EP disclosed
US-20030236274-A1 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-25 US disclosed
US-6573289-B1 Naphthalene derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-06-03 US disclosed
EP-1073640-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-02-07 EP disclosed
WO-1999054309-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236274-A1 Naphthalene derivatives, their production and use CYP17A1, CYP21A2, HSD17B1 CYP2A6 108/4885ALDH1A1 146/4885KDM4E 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.